Skye Bioscience, Inc. Common Stock (SKYE) Stock Forecast & Price Target
Skye Bioscience, Inc. Common Stock · NASDAQ
$2.02+1.74 (+619.64%)
15-min delayed · Aug 25, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering Skye Bioscience, Inc. Common Stock, 1 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $20.00 to $20.00, so the covering firms are broadly aligned. The average target of $20.00 sits 893% above the current $2.02. The rating mix has stayed broadly stable, with Buy-side ratings easing from 3 to 1 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.12 next quarter toward $-7.95 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Strong Buy
Strong Buy00%
Buy1100%
Hold00%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to Skye Bioscience, Inc. Common Stock.
As of Aug, 1 of 1 firms rate SKYE a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
SKYE EPS & revenue forecast
EPS · NEXT QUARTER
$-1.12
Range $-1.12 – $-1.12 · 1 analysts · -62% YoY
Next period, 1 analysts expect Skye Bioscience, Inc. Common Stock to earn $-1.12 a share (range $-1.12 – $-1.12), versus $-2.95 a year earlier. Full-year consensus is $-5.04, growing to $-7.95 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Skye Bioscience, Inc. Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SKYE.
#1
Jonathan Wolleben
JMP Securities · Rank #31
Buy
$4.00+98.5% to target
Overall win rate
47%
+ Follow
#2
Kristen Kluska
Cantor Fitzgerald · Rank #186
Hold
$2.00-0.7% to target
Overall win rate
38%
+ Follow
#3
George Farmer
Scotiabank · Rank #233
Buy
$20.00+892.6% to target
Overall win rate
44%
+ Follow
#4
Edward Tenthoff
Piper Sandler · Rank #327
Buy
$20.00+892.6% to target
Overall win rate
29%
+ Follow
#5
AL
Albert Lowe
Craig-Hallum
Hold
No targeton SKYE
Coverage
—
+ Follow
SKYE stock forecast FAQ
What is SKYE's average 12-month price target?+
The 1 analysts with a live target average $20.00 for Skye Bioscience, Inc. Common Stock over the next 12 months, ranging from a $20.00 high to a $20.00 low.
Is SKYE stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 1 analyst ratings, 1 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover SKYE?+
1 analysts have an active rating on Skye Bioscience, Inc. Common Stock, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering SKYE?+
Among analysts who currently cover SKYE, Jonathan Wolleben of JMP Securities has the strongest overall Quantellect track record (Rank #31). Their current call is Buy with a $4.00 target.
What is Skye Bioscience, Inc. Common Stock's projected EPS for next quarter?+
The consensus estimate is $-1.12 per share (range $-1.12 – $-1.12) across 1 analysts. Full-year EPS is projected at $-5.04, rising to $-7.95 the following year.
How much revenue is Skye Bioscience, Inc. Common Stock expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading SKYE lately?+
As of Aug, 1 of 1 firms rate SKYE a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SKYE calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
